Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLS2 | Q9UI32 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125718 | 1.00 | PRKCA (0.50) | PRKCAPRKCDCTSKCA2CA1 | |
| SCHEMBL7518686 | 1.00 | PRKCA (0.50) | PRKCAPRKCDCTSKCA2CA1 | |
| SCHEMBL112743 | 0.94 | PRKCA (0.47) | PRKCAPRKCDCTSKCA1ALDH1A1 | |
| SCHEMBL19971880 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 | |
| SCHEMBL22471650 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 | |
| SCHEMBL23930714 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 | |
| SCHEMBL2486538 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 | |
| SCHEMBL227644 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 | |
| SCHEMBL276887 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 | |
| SCHEMBL31626952 | 0.92 | PRKCA (0.50) | PRKCAPRKCDMAPK1GLS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119909-A1 | Preparation of enantiomerically enriched flavor and fragrance components | RHODIA CHIREX, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002057227-A2 | PROCESS OF ENANTIOMERICALLY ENRICHED FLAVOR AND FRAGRANCE COMPONENTS | RHODIA/CHIREX, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119909-A1 | Preparation of enantiomerically enriched flavor and fragrance components | NISCH, FASTKD5, NOTUM | PRKCA 3025/4885PRKCD 2525/4885CTSK 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.